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ABSTRACT: Two novel reversible enzyme inhibitors involved in monoamine metabolism are described. The novel 
and reversible inhibitors are the catechol-O-methyl-transferase (COMT) inhibitor, Ro 40-7592 (3,4-dihydroxy-4'-
methyl-5-nitrobenzophenone), and the monoamine oxidase type-B (MAO-B) inhibitor, Ro 19-6327 (N-(2-aminoethyl)-
5-chloro-2-pyridine carboxamide HCI). These may be of special therapeutic benefit in Parkinson's and Alzheimer's 
diseases. 
RESUME: Nouvelles approches du traitement des affections du cerveau reliees au vieillissement. Nous decrivons 
deux nouveaux inhibiteurs enzymatiques a action reversible impliques dans le metabolisme monoaminergique. Ces 
nouveaux inhibiteurs dont Taction est reversible, sont des inhibiteurs de la catechol-O-methyl-transferase (COMT), le 
Ro 40-7592 (3,4-dihydroxy-4'-methyl-5-nitrobenzophenone) et l'inhibiteur de la monoamine oxydase de type-B 
(MAO-B), Ro 19-6327 (N-(2-amino-ethyl)-5-chloro-2-pyridine carboxamide HCI). Ces produits pourraient s'averer 
particulierement benefiques dans le traitement de la maladie de Parkinson et de la maladie d'Alzheimer. 
Can. J. Neurol. Sci. 1991; 18: 384-386 
This survey deals with the main neurochemical characteris-
tics of two novel reversible enzyme inhibitors involved in 
monoamine metabolism and the rationale for their therapeutic 
use in age-related neurodegenerative brain disorders, in particu-
lar Parkinson's disease (PD) and Alzheimer's disease (AD). The 
novel and reversible inhibitors are the catechol-O-methyl-trans-
ferase (COMT) inhibitor, Ro 40-7592 (3,4-dihydroxy-4'-
methyl-5-nitrobenzophenone, and the monoamine oxidase type-
B (MAO-B) inhibitor, Ro 19-6327 (N-(2-aminoethyl)-5-chloro-
2-pyrdine carboxamide HCI). 
Chemical structure ofRo 40-7592 (left) and Ro 19-6327 (right) 
Novel Strategies for the Treatment of Parkinson's Disease 
For the symptomatic treatment of PD coadministration of the 
COMT inhibitor Ro 40-7592 with Madopar® is proposed to 
optimize the neurotransmitter replacement therapy with 3,4-
dihydroxy-phenyl-L-alanine (DOPA). The potent COMT 
inhibitor Ro 40-7592, by blocking the COMT activity intra-and 
extra-cerebrally should markedly improve the pharmacokinetics 
and pharmacodynamics of DOPA. Recent trials in healthy sub-
jects provided a first clear evidence that Ro 40-7592 (200 mg) 
given in combination with Madopar®-125 standard markedly 
enhances the bioavailability of DOPA in plasma. These new 
findings also allow us to anticipate that the pharmacokinetics of 
DOPA will be further optimized with a treatment which com-
bined Ro 40-7592 with the controlled release formulation 
Madopar® HBS.1 
Alternatively, the highly selective MAO-B inhibitor Ro 19-
6327 given with Madopar® might be useful in the therapy of PD 
because Ro 19-6327, like the irreversible MAO-B inhibitor 
selegiline (1-deprenyl), should improve dopamine (DA) neuro-
transmission by blocking the beakdown of DA in the nigrostri-
atal dopaminergic nerve terminals2'3 or adjacent cells. Recently 
it was suggested that exogenous neurotoxins could play a criti-
cal role in the process of neuronal degeneration that character-
izes PD. For instance, inhibition of MAO-B with selegiline4 or 
Ro 19-63275 dramatically reduces the conversion of l-methyl-4-
phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) into its dopaminer-
gic neuroxtoxin l-methyl-4-phenylpyridinium ion (MPP+). The 
discovery that a relatively simple compound, such as MPTP, 
produces Parkinson-like features in humans and animals and the 
fact that MAO-B inhibitors counteract MPTP-induced neurotox-
icity in experimental animals raised the suspicion that environ-
mental toxins might cause PD.6 Most important, several clinical 
studies indicate that the MAO-B inhibitor selegiline might protect 
against neurodegenerative diseases of the aging brain, e.g. in 
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PD 7 8 and in AD.9 1 0 It has also been postulated that the oxida-
tive determination of DA by MAO-B with production of hydro-
gen peroxide, in the human brain, could be deleterious for the 
nigrostriatal dopaminergic neurones. Thus, due to the abnormally 
low content of reduced glutathione and/or in the increased 
amount of ferrous iron in the substantial nigra of Parkinsonian 
patients, the hydrogen peroxide formed by deamination of DA 
might lead to the generation of oxygen free radicals which in 
turn produce lipid peroxidation, neuronal membrane damage 
and cell death.1112 In Parkinsonian patients treated with Madopar® 
or Sinemet® MAO-B inhibitors might decrease the risk of 
hydroxyl free-radical formation by reducing the formation of 
hydrogen peroxide generated from the oxidation of DA. 
According to the free-radical as well as to the neurotoxin 
hypothesis the MAO-B enzyme might play a pivotal role in the 
physiopathological processes underlying the so-called "degener-
ative" diseases of the aging brain. 
From Madopar® Standard to Madopar® HBS and the 
Rationale to Combine MadoparR with the COMT Inhibitor 
Ro 40-7592 
DOPA, the precursor amino acid of the catecholamine (CA) 
neurotransmitters including DA, administered in combination 
with peripheral DOPA decarboxylase (DDC) inhibitors, e.g. 
benserazide (Madopar®) or carbidopa (Simemet®), is still con-
sidered the major therapeutic agent for the treatment of PD.13-14 
The majority of the problems encountered in the therapy with 
DOPA originate from its complex pharmacokinetics and phar-
macodynamics.15 Being an amino acid, DOPA follows multiple 
metabolic pathways, and in the gastrointestinal tract as well as 
at the blood-brain barrier it competes with the transport of a 
number of large neutral amino acids. Competition for the blood-
brain barrier uptake occurs also between DOPA and its O-
methylated derivative 3-O-methyl DOPA (3-OMD). 3-OMD is a 
poor substrate for DDC and because of a much longer half-life 
(about 15 h) than DOPA (about 1 h) accumulates in the plasma 
of patients treated with Madopar® and Sinemet®. The ratio of 
mean plasma 3-OMD to DOPA concentrations can be as large as 
14:1 and could lead to clinical deterioration of the patients.15 
Elevated 3-OMD concentrations have sometimes been connected 
to dyskinesias or to on-off phenomena. To reduce the magnitude 
of fluctuations in plasma DOPA concentrations novel con-
trolled-release formulations e.g. Madopar® HBS16or Sinemet® 
CR415 have been recently introduced. 
The controlled-release formulations of DOPA plus DDC 
inhibitors reduce the sudden formation of peak concentrations of 
DOPA in plasma reducing the number of daily "off periods. 
The advantage of these formulations is to prolong the mainte-
nance of therapeutic DOPA levels in plasma thereby increasing 
the mobility of the patients even during the night.17 
Neurochemical Characteristics of the COMT Inhibitor Ro 
40-7592 
The nitrocatechol derivative Ro 40-7592 is a competitive 
(Ki=30 nM) inhibitor of COMT, very active in vitro (1C5Q in rat 
liver = 36 nM) and in vivo (ED5 0 for rat liver and kidney 
enzyme inhibition: 2.7 and 1.2 mg/kg p.o., 1 h). Ex vivo, a reli-
able index to assess COMT inhibition in cerebral and extracere-
bral tissues uses the decreased formation of 3-OMD and 
homovanillic acid (HVA) in rat brain and plasma.1 Several pre-
clinical studies have shown that Ro 40-7592 administered p.o. 
in combination with benserazide and DOPA almost completely 
blocks the formation of 3-OMD in rat brain and plasma.118 In 
these experiments, in addition, a long-lasting increase of DOPA 
was measured in plasma17 paralleled by a marked and prolonged 
increased in brain DA.1 In the same experimental condition, a 
marked decrease of the HVA content was measured in the brain 
with a parallel remarkable increased of 3,4-dihydroxphenyl-
lacetic acid.1 Brain nonadrenaline and H5-hydroxytryptamine 
were unaffected. 
In conclusion, by increasing the bioavailability and possibly 
prolonging the plasma half-life of DOPA as well as by reducing 
the formation of 3-OMD, Ro 40-7592, combined with peripheral 
DDC inhibitors and DOPA, e.g. in Madopar® standard or HBS 
is expected to markedly improve the therapy of PD patients. 
In healthy subjects Ro 40-7592 at single oral doses was well 
tolerated up to 800 mg and, at this dose, the compound markedly 
inhibited (> 80%) human erythrocyte COMT activity for at least 
4 h. As already observed in rat, the formation of 3-OMD was 
virtually suppressed also in human, when Madopar® 125 was 
co-administered with Ro 40-7592 (200 mg), and DOPA 
bioavailability was doubled. The available clinical data support 
the notion that Ro 40-7592 combined with Madopar® standard, 
and even more so with Madopar®-HBS, will significantly 
improve DOPA pharmacokinetics (maintaining for several hours 
optimal therapeutic concentrations of DOPA in plasma by 
avoiding the formation of sharp peak of DOPA) and prevent for-
mation and accumulation of 3-OMD in plasma and brain. It is 
anticipated that, in the near future, the combination of con-
trolled-release formulations of DOPA with Ro 40-7592 will rep-
resent an optimal therapeutic regimen by reducing the dose of 
DOPA and by prolonging interdose intervals. 
The Novel, Reversible Highly Selective MAO-B Inhibitor Ro 
19-6327 
To date, selegiline is the only MAO-B inhibitor used clinically 
as adjunct to Madopar® or Sinemet® to improve symptom fluc-
tuations in PD19 and as possible neuroprotective agent in PD7'8 
and AD.5.6 However, selegiline at relatively low doses (20 mg 
daily) and under long-term therapy does not only inhibit MAO-
B but also, to some extent, inhibits MAO-A5 with risk of hyper-
tensive crises (cheese-effect). Apart from its low specificity, the 
irreversible MAO-B inhibitor selegiline can be metabolized to 
potentially neurotoxic derivatives e.g. (-)methamphetamine and 
(-)amphetamine.20 In contrast to selegiline, Ro 19-6327 belongs 
to a new chemical class of non-toxic, mechanism-based, fully 
reversible, and highly selective MAO-B inhibitors both in vitro 
and ex vivo. Ro 19-6327 is short-lasting, since enzyme activity 
returned to control values 48 h after dosing even when the com-
pound is administered at high doses (100 7imol (23.6 mg)/kg 
p.o.) to rats. Full reversibility of MAO-B inhibition was con-
firmed directly by dialysis experiments.5 Ro 19-6327, which per 
se did not affect mean arterial blood pressure (MAP), did not 
potentiate, even at high doses, the tyramine-induced increase in 
MAP in freely moving rats.5 In black mouse striatal tissue, Ro 
19-6327 prevented MPTP-induced depletion of brain DA and 
the formation of the quaternary derivative MPP+5. Ro 19-6327, 
due to its highly selective inhibitory effect on MAO-B, is an 
excellent tool to clinically assess whether complete and selec-
tive MAO-B inhibition protects dopaminergic neurones from 
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age-associated degeneration, possibly by reducing the formation 
of free radicals or the conversion of MPTP-like compounds into 
neurotoxins in the CNS.1 In contrast to selegiline, Ro 19-6327, 
even at extremely high doses (350 mg), does not potentiate at all 
the tyramine pressor effect in healthy subjects. Moreover, this 
highly selective MAO-B inhibitor, due to its chemical structure 
cannot be converted into amphetamine-like metabolites.1 In 
healthy subjects, Ro 19-6327 at relatively low doses (40 mg), 
completely inhibited platelet MAO-B activity for about 12 h; 
the compound was well tolerated even at the high dose of 350 
mg. By positron emission tomography in man it has been shown 
that 50 mg Ro 19-6327 markedly (> 90%) inhibited brain MAO-
B for at least 12 h. Interestingly, this study showed that the time-
course of platelet MAO-B inhibition virtually paralleled the 
inhibitory effect of Ro 19-6327 on the brain enzyme.21 In con-
clusion, the highly selective, specific and non-toxic MAO-B 
inhibitor Ro 19-6327 provides a novel and safe tool to investi-
gate the physiopathological role played by MAO-B in PD and 
AD and the consequences of its inhibition in the prevention 
and/or in the therapy of these diseases. 
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